与此同时,该公司在周二收盘后表示,Idera 不再招募患者进入 tilsotolimod 与 BMS的 Yervoy 和 ...查看全文
$井寺制药(IDRA)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001558370-20-012053 Act: 34 Size: 7 MB 网页链接
$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001179110-20-010219 Size: 4 KB 网页链接
$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001179110-20-010220 Size: 4 KB 网页链接
$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001179110-20-010221 Size: 4 KB 网页链接
$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001179110-20-010222 Size: 4 KB 网页链接
$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001179110-20-010223 Size: 4 KB 网页链接
$井寺制药(IDRA)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-20-109148 Act: 34 Size: 125 KB 网页链接
$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-20-024396 Size: 20 KB 网页链接
$井寺制药(IDRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-20-024397 Size: 12 KB 网页链接
$井寺制药(IDRA)$ 8-K Current report, items 1.01, 8.01, and 9.01 Accession Number: 0001104659-20-102044 Act: 34 Size: 271 KB 网页链接